安徽医药
安徽醫藥
안휘의약
ANHUI MEDICAL AND PHARMACEUTICAL JOURNAL
2015年
5期
978-981
,共4页
胃肿瘤%新辅助化疗%外科手术%预后
胃腫瘤%新輔助化療%外科手術%預後
위종류%신보조화료%외과수술%예후
stomach neoplasms%neoadjuvant chemotherapy%aurgery%prognosis
目的：观察奥沙利铂联合卡培他滨方案新辅助化疗治疗进展期胃癌患者的临床疗效、毒副作用及生存状况。方法回顾性分析2011年7月—2012年9月该医院收治的65例局部进展期可切除胃腺癌患者的临床资料。其中33例患者（实验组）完成新辅助化疗后接受开放手术治疗，32例患者（对照组）入院后直接行手术，分析比较两组患者的根治效果、术后并发症情况及生存情况等。结果实验组患者R0切除32例、R1切除1例，对照组患者R0切除24例、R1切除8例，两组比较，差异有统计学意义（χ2＝4．861，P＜0．05）；阳性淋巴结检出数目分别为（4．55±1．48）枚和（6．38±2．27）枚（t＝－3．838，P＜0．05）；淋巴结清扫数目分别为（21．24±2．67）枚和（20．19±2．71）枚及术后并发症发生数分别为3例和3例，两组差异均无统计学意义（P＞0．05）。实验组平均术中失血量（434．29±86．64）mL，对照组为（190．97±47．91）mL，差异有统计学意义（P＜0．05）。实验组患者的中位总生存时间为23．5个月，对照组为17．7个月（P＝0．138）。结论奥沙利铂联合卡培他滨新辅助化疗化疗毒副作用可耐受，可提高进展期胃癌R0切除率，降低淋巴结转移率，延长患者的生存时间。
目的：觀察奧沙利鉑聯閤卡培他濱方案新輔助化療治療進展期胃癌患者的臨床療效、毒副作用及生存狀況。方法迴顧性分析2011年7月—2012年9月該醫院收治的65例跼部進展期可切除胃腺癌患者的臨床資料。其中33例患者（實驗組）完成新輔助化療後接受開放手術治療，32例患者（對照組）入院後直接行手術，分析比較兩組患者的根治效果、術後併髮癥情況及生存情況等。結果實驗組患者R0切除32例、R1切除1例，對照組患者R0切除24例、R1切除8例，兩組比較，差異有統計學意義（χ2＝4．861，P＜0．05）；暘性淋巴結檢齣數目分彆為（4．55±1．48）枚和（6．38±2．27）枚（t＝－3．838，P＜0．05）；淋巴結清掃數目分彆為（21．24±2．67）枚和（20．19±2．71）枚及術後併髮癥髮生數分彆為3例和3例，兩組差異均無統計學意義（P＞0．05）。實驗組平均術中失血量（434．29±86．64）mL，對照組為（190．97±47．91）mL，差異有統計學意義（P＜0．05）。實驗組患者的中位總生存時間為23．5箇月，對照組為17．7箇月（P＝0．138）。結論奧沙利鉑聯閤卡培他濱新輔助化療化療毒副作用可耐受，可提高進展期胃癌R0切除率，降低淋巴結轉移率，延長患者的生存時間。
목적：관찰오사리박연합잡배타빈방안신보조화료치료진전기위암환자적림상료효、독부작용급생존상황。방법회고성분석2011년7월—2012년9월해의원수치적65례국부진전기가절제위선암환자적림상자료。기중33례환자（실험조）완성신보조화료후접수개방수술치료，32례환자（대조조）입원후직접행수술，분석비교량조환자적근치효과、술후병발증정황급생존정황등。결과실험조환자R0절제32례、R1절제1례，대조조환자R0절제24례、R1절제8례，량조비교，차이유통계학의의（χ2＝4．861，P＜0．05）；양성림파결검출수목분별위（4．55±1．48）매화（6．38±2．27）매（t＝－3．838，P＜0．05）；림파결청소수목분별위（21．24±2．67）매화（20．19±2．71）매급술후병발증발생수분별위3례화3례，량조차이균무통계학의의（P＞0．05）。실험조평균술중실혈량（434．29±86．64）mL，대조조위（190．97±47．91）mL，차이유통계학의의（P＜0．05）。실험조환자적중위총생존시간위23．5개월，대조조위17．7개월（P＝0．138）。결론오사리박연합잡배타빈신보조화료화료독부작용가내수，가제고진전기위암R0절제솔，강저림파결전이솔，연장환자적생존시간。
Objective To evaluate the efficacy and toxicity of combination therapy of oxaliplatin in combination with capecitabine regi-men in patients with advanced gastric cancer.Methods The clinical data of 65 patients with advanced gastric cancer(stage IIb and II-Ic)admitted to the First Affiliated Hospital of Anhui Medical University from July 201 1 to September 2012 were retrospectively ana-lyzed.All the patients were divided into the neoadjuvant chemotherapy group(33 cases)and the surgery alone group(32 cases).The ef-ficacy of radical resection,postoperative complication rate,and overall survival of the 2 groups were compared.Results The numbers of patients who received R0 and R1 resection in the neoadjuvant chemotherapy group were 32 and 1 ,which were significantly different from 24 and 8 in the surgery alone group(χ2 =4.861,P<0.05).The number of lymph node metastasis in the treatment group(4.55 ± 1.48)was significantly lower than that in the control arm(6.38 ±2.27,t=-3.838,P<0.05).There was no significant difference in the number of postoperative complication cases(3 cases vs 3 cases)and the number of lymph node dissection(21.24 ±2.67 vs 20.19 ± 2.71)between the two groups(P >0.05).The average volume of peri-operative bleeding in the treatment group(434.29 ±86.64)mL was significantly higher than that in the control arm[(190.97 ±47.91)mL,P<0.05].The survival analysis indicated that the median overall survival was longer in the neoadjuvant chemotherapy group(23.5 months)in comparison with this in the surgery along group (17.7 months),but no significant difference was found(P=0.138).Conclusions The combined neoadjuvant chemotherapy regimen of oxaliplatin and capecitabine can be effective.Patients tolerance and compliance are satisfying.It can improve the R0 resection rate in patients with advanced gastric cancer,and reduce lymph node metastasis and improve survival.
